In a randomized, double-blind phase 3 trial, the anti-α 4}β 7} integrin monoclonal antibody vedolizumab plus standard prophylaxis was superior to placebo plus prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation.
All Keywords
【저자키워드】 Randomized controlled trials, Graft-versus-host disease,
【저자키워드】 Randomized controlled trials, Graft-versus-host disease,